Trends in the healthcare burden of hepatitis C after the introduction of direct-acting antivirals in Japan, 2013-2022: A national claims database study in Japan
During the 10-y DAA era, the healthcare burden of hepatitis C declined substantially in Japan. Enhanced efforts in prevention, screening, and treatment are critical for the eradication of hepatitis C, particularly among high-risk populations, such as individuals with HIV.
Authors
- Naohiro Mitsutake (ORCID: https://orcid.org/0000-0003-1809-5426)
- Kazuo Goda (ORCID: https://orcid.org/0000-0003-0618-4157)
- Hiromasa Yoshimoto (ORCID: https://orcid.org/0000-0001-9702-2879)
- Hideki Hashimoto (ORCID: https://orcid.org/0000-0003-3663-6564)
- Naoki Kanda (ORCID: https://orcid.org/0000-0001-8003-534X)
- Shuji Hatakeyama (ORCID: https://orcid.org/0000-0003-2684-1695)
- S. Yamashita
Institutions
- Jichi Medical University (JP)
- Institute for Health Economics and Policy (JP)
- Hitachi General Hospital (JP)
- Jichi Medical University Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- International Journal of Infectious Diseases
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1016/j.ijid.2025.108043
- Citations
- 2
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science